ISSN Print 2500–1094
ISSN Online 2542–1204
Bulletin of RSMU
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
ORIGINAL RESEARCH
Assessment of metastatic traits of the cells with hybrid phenotype in breast cancer
About authors
1 Siberian State Medical University, Tomsk, Russia
2 Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
3 Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia
4 Regional Children’s Clinical Hospital, Vladimir, Russia
Correspondence should be addressed: Olga E. Savelieva
Litovskaya, 2, Saint-Petersburg, 194100; ur.liam@anihcehc_aglo
About paper
Funding: the study was supported by the RSF grant № 21-15-00140.
Author contribution: Mukhamedzhanov RK — literature analysis, data acquisition and statistical processing, manuscript writing; Grigoryeva ES — data acquisition and analysis, manuscript writing; Tashireva LA — study design, manuscript editing; Perelmuter VM — data interpretation, manuscript editing; Zavyalova MV — study planning, manuscript editing; Savelieva OE — study planning and management, data analysis and interpretation, manuscript writing.
Compliance with the ethical standards: the study was approved by the Ethics Committee of the Cancer Research Institute, Tomsk National Research Medical Center (protocol № 10 of 24 April 2015) and conducted in accordance with the Federal Laws of the Russian Federation (№ 152, 323, etc.), the Declaration of Helsinki (1964) and all subsequent amendments and supplements regulating the research involving human biomaterials. The informed consent to study participation was submitted by all subjects.
Received: 2023-07-04
Accepted: 2023-08-22
Published online: 2023-08-31
|
Fig. 1. Gating strategy for the populations of cells with hybrid phenotype and expression of the leukocyte, epithelial, stem and EMT markers (А), and integrinreceptors (B) exemplified by the cells circulating in blood
Fig. 2. Number of cells with hybrid phenotype in blood and primary tumors of patients with breast cancer. А. Number of cells with various combinations of the CD45 leukocyte and EpCAM and CK7/8 epithelial markers expression. B. Number of cells showing stem features. C. Number of cells showing features of epithelial–mesenchymal transition
Fig. 3. Number of cells with hybrid phenotype showing expression of β3, β4, and αVβ5 integrin molecules in blood of patients with breast cancer
Fig. 4. Stem features and integrin expression in circulating cells with hybrid phenotype in breast cancer patients with lymph node metastasis
Fig. 5. Stem and EMT features in circulating cells with hybrid phenotype in breast cancer patients with distant metastasis
Fig. 6. Integrin expression by cells with hybrid phenotype in breast cancer patients with distant metastasis
Table 1. Characteristics of patients with invasive breast carcinoma of no special type
Table 2. Frequency of cells with hybrid phenotype in patients with breast cancer
Table 3. Frequency of cells with hybrid phenotype showing stem features in patients with breast cancer
Table 4. Frequency of cells with hybrid phenotype showing EMT features in patients with breast cancer
Table 5. Frequency of cells with hybrid phenotype showing integrin expression in patients with breast cancer
